US 11,969,500 B2
Implantable depots for the controlled release of therapeutic agents
Karun D. Naga, Los Altos, CA (US); Hanson S. Gifford, III, Woodside, CA (US); Stephen W. Boyd, San Francisco, CA (US); Patrick H. Ruane, El Dorado Hills, CA (US); Jackie Joe Hancock, Berkeley, CA (US); Michael Feldstein, San Francisco, CA (US); Koon Kiat Teu, Singapore (SG); Honglei Wang, Singapore (SG); Jingnan Luo, Singapore (SG); and Daniel Boon Lim Seet, Singapore (SG)
Assigned to Foundry Therapeutics, Inc., Menlo Park, CA (US)
Filed by Foundry Therapeutics, Inc., Menlo Park, CA (US)
Filed on Nov. 10, 2021, as Appl. No. 17/454,320.
Application 17/454,320 is a continuation of application No. 17/248,949, filed on Feb. 15, 2021, granted, now 11,224,570.
Application 17/248,949 is a continuation of application No. 16/840,215, filed on Apr. 3, 2020, granted, now 11,202,754.
Application 16/840,215 is a continuation of application No. PCT/US2018/054777, filed on Oct. 6, 2018.
Claims priority of provisional application 62/723,478, filed on Aug. 28, 2018.
Claims priority of provisional application 62/670,721, filed on May 12, 2018.
Claims priority of provisional application 62/640,571, filed on Mar. 8, 2018.
Claims priority of provisional application 62/569,349, filed on Oct. 6, 2017.
Prior Publication US 2022/0117885 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/445 (2006.01); A61K 47/34 (2017.01)
CPC A61K 9/0024 (2013.01) [A61K 31/445 (2013.01); A61K 47/34 (2013.01)] 31 Claims
 
1. A depot for treating postoperative pain, the depot comprising:
a therapeutic region including a biodegradable polymer, an analgesic, and a releasing agent, the therapeutic region having a first surface, a second surface opposite the first surface, and an exposed sidewall between the first and second surfaces;
a first control region covering the first surface of the therapeutic region and having a thickness no greater than 1/50 of a thickness of the therapeutic region, the first control region comprising a biodegradable polymer; and
a second control region covering the second surface of the therapeutic region and having a thickness no greater than 1/50 of the thickness of the therapeutic region, the second control region comprising a biodegradable polymer,
wherein the analgesic constitutes at least 50% of a total weight of the depot, and
wherein, when the depot is implanted at a treatment site, the depot is configured to release the analgesic at the treatment site for a release duration of no less than 14 days, wherein the depot is configured to release the analgesic at a first rate for an initial period of the release duration and at a second rate for a subsequent period of the release duration, the second rate being slower than the first rate.